<DOC>
	<DOC>NCT00333567</DOC>
	<brief_summary>This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic knee surgery</brief_summary>
	<brief_title>Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery</brief_title>
	<detailed_description />
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Patients who need scheduled minor ambulatory arthroscopic knee surgery. Patients with any surgical or medical conditions which could place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>arthroscopic knee surgery</keyword>
	<keyword>cyclooxygenase-2 inhibitors</keyword>
	<keyword>lumiracoxib</keyword>
	<keyword>COX189</keyword>
	<keyword>Ambulatory arthroscopic knee surgery</keyword>
</DOC>